19 Oct 2020 --- Researchers are calling for the US Food and Drug Administration (FDA) to be more transparent about its industry ties. A cross-sectional study found that parties with financial ties to industry made nearly two-thirds of the comments on the FDA’s proposed regulatory framework for artificial intelligence/machine learning (AI/ML)-based software as a medical device.
